Skip to main content
TCRT logo

Alaunos Therapeutics, Inc.

TCRTNASDAQHealthcareBiotechnology

$2.63Today:- (-)1Y −28.99%

As of Oct 16, 2026 close

Market cap
$5.30M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.72$4.50
Volume (live)
-
Avg. volume (3M)
14.27M

Alaunos Therapeutics (TCRT) Income Statement

Alaunos Therapeutics reported revenue of $5.00K in fiscal 2025 (fiscal year ended Dec 31, 2025), down 50.0% from $10.00K a year earlier. Alaunos Therapeutics posted a net loss of $4.18M, compared with a net loss of $4.68M a year earlier. Gross margin was -27160.0% and operating margin -84500.0%.

Alaunos Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Alaunos Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue0.010.010.012.920.400.000.000.156.39
Cost of Revenue1.360.3616.2822.5247.281.130.630.000.00
Gross Profit-1.360.010.012.92-46.88-1.13-0.630.156.39
Operating Expenses
Research & Development1.360.3616.2825.0249.6452.7038.3334.1345.08
Selling, General & Administrative2.874.4612.2213.1427.5626.5418.9019.9214.80
Operating Expenses2.874.8234.8738.2977.2179.2357.2354.0559.88
Operating Income-4.23-4.81-34.27-35.11-76.81-80.36-57.86-53.91-53.49
Other Income/Expense
Interest Income0.000.000.000.000.000.000.000.000.00
Interest Expense0.000.00-1.92-3.151.190.000.000.000.83
Other Income/Expense0.050.13-1.75-5.25-0.750.39-59.940.79-0.83
Income
Income Before Tax-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12-54.32
Income Tax Expense0.000.000.000.000.000.000.000.000.00
Net Income-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12-54.32
Net Income - Continuous Operations-4.18-4.68-35.14-37.73-78.75-79.98-117.80-53.12-54.32
Net Income - Discontinued Operations---------
EBITDA-4.17-4.81-26.18-29.98-74.97-78.85-117.17-53.33-53.12
EBIT-4.23-4.81-28.49-32.74-77.56-80.36---
Depreciation & Amortization0.010.002.322.762.601.130.630.570.37
Earnings Per Share
Basic EPS-2.00-3.00-22.00-26.00-55.00-56.00-159.00-56.00-59.00
Diluted EPS-2.00-3.00-22.00-26.00-55.00-56.00-159.00-55.00-59.00
Basic Shares Outstanding1.951.601.601.451.431.401.120.960.91
Diluted Shares Outstanding1.951.601.601.451.431.401.120.960.91

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Alaunos Therapeutics Financial Statements

What was Alaunos Therapeutics's revenue in fiscal 2025?

Alaunos Therapeutics reported revenue of $5.00K in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 50.0% from $10.00K a year earlier.

Is Alaunos Therapeutics profitable?

No. Alaunos Therapeutics reported a net loss of $4.18M in fiscal 2025. In fiscal 2024 it lost $4.68M.

What is Alaunos Therapeutics's operating margin?

Alaunos Therapeutics's operating income was −$4.22M on revenue of $5.00K in fiscal 2025, an operating margin of -84500.0%, compared with -48120.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition